Selumetinib granule formulation clinical trials

Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN

This study is testing a new liquid form of the medicine selumetinib for children aged 1 to 6 with a type of tumour linked to Neurofibromatosis Type 1 (NF1). It aims to find the right dose and check if it's safe and helps shrink the tumours.